David Pasquier
Prof David Pasquier is an expert in Radiotherapy at Centre Oscar Lambret (France). As of October 2026, ScienceLeadR ranks David Pasquier in the top 1% of experts worldwide for Prostatic Diseases, Urogenital Neoplasms and Genital Diseases, Male. David Pasquier has authored 339 publications, the most recent in 2027, and is an investigator in 23 clinical trials, 9 of them ongoing. SLR score: 1,351 (community average: 125). How the SLR is computed.
LeadR Profile
Radiotherapy
Subspecialties: Oncology - Urology - Nuclear Medicine
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2015 - 2027
Number : 339
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Postoperative radiotherapy after radical cystectomy for muscle-invasive bladder cancer: Patient selection, target delineation and contemporary evidence. PMID 42933265 — radiotherapy, radiotherapy, image-guided, urinary bladder, urinary bladder neoplasms, margins of excision, muscles, neoplasms, radiotherapy, adjuvant, cystectomy, therapeutics | Cancer Radiother | 2026 | 0 |
| Quality of life after trimodal treatment for muscle-invasive bladder cancer. PMID 42933261 — urinary bladder, urinary bladder neoplasms, quality of life, muscles, neoplasms, cystectomy, patient reported outcome measures, therapeutics, prospective studies | Cancer Radiother | 2026 | 0 |
| Reirradiation for prostate cancer local recurrence: State of the art and future directions. PMID 42933257 — radiotherapy, tomography, neoplasms, prostate, re-irradiation, drug-related side effects and adverse reactions, prostatic neoplasms, therapeutics | Cancer Radiother | 2026 | 0 |
| Local treatment for HER2-positive or triple negative second ipsilateral breast cancer event: A propensity score-matched analysis of the GEC-ESTRO database. PMID 42612561 — mastectomy, breast neoplasms, neoplasms, propensity score, mastectomy, segmental, breast, therapeutics | Breast | 2026 | 0 |
| Reirradiation of locally recurrent prostate Cancer: a review of prospective evidence and delineation and planning strategies from the reirradiation Collaborative group (ReCOG). PMID 42540621 — brachytherapy, neoplasms, prostate, uncertainty, re-irradiation, prostatic neoplasms, therapeutics, prospective studies | Clin Transl Radiat Oncol | 2026 | 0 |
Clinical Studies 23
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
9 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Best Salvage Treatment for High risk Relapsing Prostate Cancer (PEACE 9 ESCALATE RT) NCT07782112 — androgen antagonists, radiotherapy, blood, pharmaceutical preparations, androgens, neoplasms, prostate, prescriptions, hormones, neoplasm metastasis, prostatic neoplasms, beds, therapeutics, prostatectomy, salvage therapy, men | Phase 3 | Not yet recruiting | 2026 |
| Treatment with darolutamide radiation therapy for patients with a castration resistant cancer and metastases detected by functional imaging 2023-509787-15-00 — radiotherapy, safety, lymph nodes, neoplasms, classification, prostate, positron emission tomography computed tomography, neoplasm metastasis, lymph, prostatic neoplasms, castration, therapeutics | Phase 3 | Not yet recruiting | 2025 |
| Multicentre Phase II Trial Evaluating Stereotactic Body Radiotherapy on Ultra central Lung Tumors on MR Linac NCT07733219 — radiotherapy, radiotherapy, image-guided, lung, lymph nodes, neoplasms, lung neoplasms, lymph, therapeutics | N/A | Not yet recruiting | 2026 |
| Treatment with darolutamide radiation therapy for patients with a castration resistant cancer and metastases detected by functional imaging 2023-507482-26-00 — radiotherapy, choline, radiosurgery, tomography, positron-emission tomography, neoplasms, prostate, neoplasm metastasis, prostatic neoplasms, castration, therapeutics | Phase 3 | Recruiting | 2024 |
| Evaluation of the Stereotactic MR guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers NCT07097064 — radiotherapy, pancreatic neoplasms, neoplasms, adenocarcinoma, radiotherapy, conformal, drug therapy, chemotherapy | Phase 2 | Not yet recruiting | 2025 |
LeadR Networks
Main global connection map